Table 3.
Multiorgan ECV Response to Treatment 12 Months After Initiating Chemotherapy, Compared With the Hematologic Response and Repeat SAP Scintigraphy at 12 Months
| All Patients Who Had Repeat CMR With ECV Mapping at 12 mo (N = 120, Liver ECV Measurable in 108 Patients and Spleen Measurable in 108 Patients) | ||||
|---|---|---|---|---|
| Hematologic Response | Complete Response (n = 50, 41.7%) | Very Good Partial Response (n = 35, 29.2%) | Partial Response (n = 24, 20.0%) | No Response (n = 11, 9.2%) |
| Liver ECV regression | 11 | 5 | 0 | 0 |
| Spleen ECV regression | 8 | 7 | 2 | 0 |
| Cardiac ECV regression | 19 | 8 | 0 | 0 |
| Stable liver ECV | 33 | 27 | 14 | 9 |
| Stable spleen ECV | 36 | 23 | 16 | 11 |
| Stable cardiac ECV | 25 | 23 | 12 | 7 |
| Liver ECV progression | 1 | 2 | 4 | 2 |
| Spleen ECV progression | 1 | 2 | 2 | 0 |
| Cardiac ECV progression | 6 | 4 | 12 | 4 |
| Patients With Repeat SAP Scintigraphy and CMR with ECV Mapping at 12 mo (N = 79, Liver ECV Measurable in 73 and Spleen Measurable in 75) | ||||
|---|---|---|---|---|
| Liver Response | Liver Regression on SAP (n = 4) | Stable Liver on SAP (n = 65) | Liver Progression on SAP (n = 4) | |
| Liver ECV regression | 2 | 10 | 0 | |
| Stable liver ECV | 2 | 54 | 1 | |
| Liver ECV progression | 0 | 1 | 3 | |
| Spleen Response | Spleen Regression on SAP Scintigraphy (n = 11) | Stable Spleen on SAP Scintigraphy (n = 61) | Spleen Progression on SAP Scintigraphy (n = 3) | |
|---|---|---|---|---|
| Spleen ECV regression | 7 | 7 | 0 | |
| Stable spleen ECV | 4 | 53 | 1 | |
| Spleen ECV progression | 0 | 1 | 2 | |